CLCN7

Across TCGA pan-cancer cohorts, CLCN7 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CLCN7 data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CLCN7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLCN7 expression acts as an unfavorable survival marker.

KIRC, UCEC, and LUAD are the cancer types where CLCN7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.148	0.813	<.001	48	view →
UCEC	OS	Median	IV	0.066	0.755	<.001	12	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	9	view →
STAD	OS	Median	II,III,IV	0.255	0.659	.046	6	view →
LIHC	OS	Median	All	0.167	0.688	.035	6	view →
SKCM	OS	Median	II,III,IV	0.245	0.731	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CLCN7–KIRC (OS)

Open the KIRC breakdown →